UNSPSC 51143600: Combination antivertigo agents

This classification denotes combination drugs used in the treatment of an illusion of movement, either of the external world revolving around the individual or of the individual revolving in space, a condition called Vertigo, hence the term ANTIVERTIGO AGENTS. Typical combination antivertigo agent constituents are dimenhydrinate and niacin.

UNSPSC 51143600 Combination antivertigo agents is a Class code that encompasses pharmaceutical procurement by state and local health agencies, though recent solicitation activity shows significant misalignment between the code's nominal scope and actual buying patterns. Rather than antivertigo medications, state and local governments are using this code to solicit naloxone and drug deactivation systems (Seminole County, Florida), generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing arrangements (Minnesota Multistate Cooperative Purchasing Alliance), and exploratory requests for information on direct-to-manufacturer prescription programs (Texas Health and Human Services Commission). The issuing bodies include county health departments, state health and human services commissions, and cooperative purchasing alliances that aggregate demand across multiple jurisdictions. Procurement vehicles range from competitive sealed bids to RFPs and preliminary RFIs designed to gather market intelligence before formal solicitation.

Geographically, recent activity is concentrated in Florida, Minnesota, and Texas, with the cooperative purchasing vehicle extending reach to Oregon and other participating states. The Seminole County IFB (IFB60459723LAS) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, requiring quarterly deliveries and fixed-fee pricing. The Minnesota Multistate Cooperative Purchasing Alliance RFP (S1070000015802) established multiple contracts for generic pharmaceuticals and OTC products with a March 26, 2026 deadline, requiring vendors to supply through three authorized wholesalers with contracts effective July 1, 2026, and pricing weighted 75 percent toward competitiveness. The Texas HHS RFI (HHS0017013) issued in April 2026 sought vendor information on direct-to-manufacturer prescription capabilities to inform future formal procurement strategy. The code shows limited alignment with its abstract definition; buyers should verify coding accuracy in specific opportunities before pursuing.